SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot (DRB) is surging in popularity due to its unique ties to AI-generated wealth and its association with the Bankr ecosystem on the Base network. Investors are actively discussing its potential for significant growth, drawing speculative interest from its narrative as an AI-to-AI innovation with ties to the Grok project.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive is gaining significant momentum and community attention following a strategic collaboration with Synthetix to develop derivatives on the Ethereum network. Investors are actively discussing the protocol's healthy consolidation patterns, consistent upward price movement, and the potential impact of its ongoing buyback mechanism.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors gear up for a highly anticipated partnership announcement, with many community members speculating about potential integration with industry giants like Ripple or ADP. While some participants are actively accumulating and staking in anticipation of long-term utility gains, others remain skeptical, fueling a heated debate between those confident in the project's real-world payroll infrastructure and those concerned about price stagnation.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant volatility driven by intense retail interest in its potential for a short squeeze and ongoing speculation about institutional accumulation. While some traders are capitalizing on the stock's recent aggressive price appreciation, others remain highly skeptical of its long-term viability, debating whether the rally is a genuine turnaround or a heavily manipulated retail trap.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is seeing significant community buzz driven by developments in RWA tokenization and institutional partnerships, with investors closely watching for impacts from pending regulatory legislation. Discussion centers on a long-term bullish outlook for its role as essential financial infrastructure despite frustration over recent sideways price action.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is capturing significant attention as investors navigate the impact of escalating Middle East conflict on natural gas supply chains and volatility in the energy sector. Market participants are actively debating whether geopolitical risks and production disruptions in the Strait of Hormuz will sustain price momentum or if seasonal demand patterns and high inventory levels will ultimately lead to a correction.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending as investors debate whether the current valuation near all-time lows represents a deep-value opportunity or a sign of deeper structural decline. While the community remains divided over management's expansion strategy and the lack of a permanent CEO, sentiment is being bolstered by strong physical traffic at new locations and the belief that the stock is oversold due to end-of-year tax loss harvesting.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently a focal point of community debate as investors weigh the potential long-term benefits of the Polkadot 2.0 upgrade and new supply cap tokenomics against persistent bearish price action. While some participants are actively accumulating the asset and staking to earn yields, others are expressing significant frustration over recent performance and the lack of broader market adoption.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is capturing market attention as the community rallies around its unique blend of cannabis culture and on-chain engagement ahead of 4/20. Supporters are actively participating in AI-driven promotional competitions and highlighting the project's steady, organic growth as a grassroots alternative to traditional cannabis stocks.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is garnering significant community attention as investors debate its potential role in the surging AI data center market, particularly following the introduction of standardized 12.5 MW power blocks. While some shareholders express frustration over persistent fundamental headwinds and limited contract announcements compared to peers like Bloom Energy, others remain optimistic that the company's modular technology and strategic alignment with key partners like ExxonMobil position it to capture long-term upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00

Roth Mkm decreased their price objective on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Monday...

What's Going On With Cingulate Stock Today?

Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.read more...

Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Cingulate (NASDAQ:CING - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28...

Cingulate (CING) Expected to Announce Earnings on Thursday

Cingulate (NASDAQ:CING) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-cingulate-inc-stock...

<ul class="summary-bullets"><li>The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected to be issued.</li><li>The filing covers drug-delivery technologies for neurological treatments, including ADHD.</li><li>The technology supports Cingulate’s Precision Timed Release (PTR) platform, used in CTx-1301, an ADHD drug.</li></ul>Shares of Cingulate, Inc. (CING) jumped over 4% in overnight trading on Sunday after the U.S. Patent and Trademark Office (PTO) cleared a key patent application tied to the company’s ADHD drug platform, adding another potential catalyst ahead of a major regulatory decision expected in May.<a href="https://stocktwits.com/symbol/CING">CING stock</a> snapped four straight sessions of gains on Friday to end nearly 5% lower at $8.69.<h2 class="st-heading-2">Patent Office Clears Cingulate ADHD Drug Patent</h2>Patent records show the USPTO has allowed a patent titled “Trimodal, Precision-Timed Pulsatile Release Tablet.” The application, filed in November 2023, is now listed with the status “Allowed - Notice of Allowance Not Yet Mailed” as of Sunday. An allowed status means the patent examiner has approved the claims, and the patent will be issued once final administrative steps are completed.The inventors listed on the filing include Matthew Brams, Cingulate’s chief medical officer, Raul Silva, its chief science officer, and Arthur Straughn, a co-founder of the company. It also names Cingulate as the applicant. The application covers drug-delivery technologies classified for neurological treatments, including attention-deficit/hyperactivity disorder (ADHD).<h2 class="st-heading-2">How Cingulate’s ADHD Drug Technology Works</h2>The patent application centers on a trimodal pulsatile-release tablet that releases medication at multiple timed intervals throughout the day. The tech aligns with Cingulate’s Precision Timed Release (PTR) platform, which the company is using to develop next-generation treatments for ADHD and other neurological conditions.The approach aims to address common challenges with stimulant medications, including midday rebound and the need for multiple doses. CTx-1301 uses dexmethylphenidate, a stimulant already approved to treat ADHD, delivered through Cingulate’s Precision Timed Release platform. It releases dexmethylphenidate in three timed pulses, with the final dose delivered around the time when many extended-release stimulant medications begin to wear off. The company said the design aims to provide rapid symptom relief in the morning and consistent symptom control into the evening.In 2024, the company received a European patent for its CTx-1301, which covers up to 30 European territories, including the UK. The company also holds patents in Australia, Canada, and Israel.<h2 class="st-heading-2">FDA Decision Looms For ADHD Drug</h2>The patent development comes ahead of a key regulatory milestone for Cingulate’s lead program. In October 2025, the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for CTx-1301 for the treatment of ADHD in children and adults. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of May 31.The application is being reviewed under a regulatory pathway that allows companies to reference existing data for approved ingredients while showing new clinical benefits through different delivery technologies. Cingulate completed Phase 3 trials in adult and pediatric patients before submitting the application. The studies showed improvements in ADHD symptoms and demonstrated sustained efficacy across the day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CING shifted to ‘extremely bullish’ from the ‘bullish’ zone over the past month amid a 675% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cing_ss_png_1c541a03cd.webp" alt="cing ss.png" width="968" height="141"><figcaption>CING sentiment and message volume as of March 15 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/stockchacing/message/647581086">said</a>, “Can’t wait for Monday, interesting week ahead of us.”<stembedurl>https://stocktwits.com/stockchacing/message/647581086</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/fullobullz/message/647578844">said</a>, “Fuel up the rockets, time to ride to moon.”<stembedurl>https://stocktwits.com/fullobullz/message/647578844</stembedurl>CING stock has doubled so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CING stock has doubled so far this year. (Photo credit: Getty Images)

Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst

The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Equity

Cingulate (NASDAQ:CING) Trading Up 6.5% - Here's What Happened

Cingulate (NASDAQ:CING) Shares Up 6.5% - Here's Why...

Cingulate (NASDAQ:CING) CEO Shane Schaffer Purchases 6,809 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer acquired 6,809 shares of the company's stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost...

Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CFO Jennifer Callahan purchased 4,864 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer purchased 6,809 shares of Cingulate stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average...

Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) Director Peter Werth acquired 19,455 shares of the company's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CINGCingulate Inc